Suppr超能文献

甲基化依赖性组织因子抑制导致 IDH1 突变型脑胶质瘤恶性程度降低。

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.

机构信息

Department of Neurological Surgery, Northwestern University, Chicago, Illinois.

Department of Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois.

出版信息

Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.

Abstract

PURPOSE

Gliomas with mutations (IDH1) are less aggressive than IDH1 wild-type (IDH1) gliomas and have global genomic hypermethylation. Yet it is unclear how specific hypermethylation events contribute to the IDH1 phenotype. Previously, we showed that the gene encoding the procoagulant tissue factor (TF), , is among the most hypermethylated and downregulated genes in IDH1 gliomas, correlating with greatly reduced thrombosis in patients with IDH1 glioma. Because TF also increases the aggressiveness of many cancers, the current study explored the contribution of TF suppression to the reduced malignancy of IDH1 gliomas. TF expression was manipulated in patient-derived IDH1 and IDH1 glioma cells, followed by evaluation of and behavior and analyses of cell signaling pathways.

RESULTS

A demethylating agent, decitabine, increased transcription and TF-dependent coagulative activity in IDH1 cells, but not in IDH1 cells. TF induction enhanced the proliferation, invasion, and colony formation of IDH1 cells, and increased the intracranial engraftment of IDH1 GBM164 from 0% to 100% ( = 0.0001). Conversely, TF knockdown doubled the median survival of mice engrafted with IDH1/EGFRvIII GBM6, and caused complete regression of IDH1/EGFR GBM12 ( = 0.001). and effects were linked to activation of receptor tyrosine kinases (RTK) by TF through a Src-dependent intracellular pathway, even when extracellular RTK stimulation was blocked. TF stimulated invasion predominately through upregulation of β-catenin.

CONCLUSIONS

These data show that TF suppression is a component of IDH1 glioma behavior, and that it may therefore be an attractive target against IDH1 gliomas.

摘要

目的

与 IDH1 野生型(IDH1)胶质瘤相比,携带 突变的神经胶质瘤侵袭性较低,且具有全基因组超甲基化。然而,目前尚不清楚特定的超甲基化事件如何导致 IDH1 表型。先前,我们发现编码促凝血组织因子(TF)的基因 在 IDH1 神经胶质瘤中是最超甲基化和下调的基因之一,这与 IDH1 神经胶质瘤患者的血栓形成大大减少有关。由于 TF 也会增加许多癌症的侵袭性,因此目前的研究探讨了 TF 抑制对降低 IDH1 神经胶质瘤恶性程度的贡献。在源自 IDH1 和 IDH1 神经胶质瘤患者的细胞中操纵 TF 表达,然后评估 和 行为,并分析细胞信号通路。

结果

去甲基化剂地西他滨增加了 IDH1 细胞中的 转录和 TF 依赖性凝血活性,但对 IDH1 细胞没有影响。TF 诱导增强了 IDH1 细胞的增殖、侵袭和集落形成能力,并使 IDH1 GBM164 从颅内植入率为 0%增加到 100%(=0.0001)。相反,TF 敲低使 IDH1/EGFRvIII GBM6 荷瘤小鼠的中位生存期增加了一倍,并导致 IDH1/EGFR GBM12 完全消退(=0.001)。 和 效应与 TF 通过Src 依赖性细胞内途径激活受体酪氨酸激酶(RTK)有关,即使阻断细胞外 RTK 刺激也是如此。TF 刺激侵袭主要是通过上调 β-连环蛋白。

结论

这些数据表明,TF 抑制是 IDH1 神经胶质瘤行为的一个组成部分,因此可能是针对 IDH1 神经胶质瘤的有吸引力的靶点。

相似文献

1
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.
2
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
J Natl Cancer Inst. 2012 Oct 3;104(19):1458-69. doi: 10.1093/jnci/djs357. Epub 2012 Sep 3.
3
Mutant IDH1 and thrombosis in gliomas.
Acta Neuropathol. 2016 Dec;132(6):917-930. doi: 10.1007/s00401-016-1620-7. Epub 2016 Sep 23.
4
Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Clin Cancer Res. 2014 Nov 15;20(22):5808-22. doi: 10.1158/1078-0432.CCR-14-0234. Epub 2014 Sep 15.
5
Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
FASEB J. 2019 Jan;33(1):557-571. doi: 10.1096/fj.201800907RR. Epub 2018 Jul 12.
6
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
J Neurooncol. 2021 Sep;154(2):159-170. doi: 10.1007/s11060-021-03829-0. Epub 2021 Aug 23.
8
Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
J Neurooncol. 2018 Jun;138(2):241-250. doi: 10.1007/s11060-018-2799-3. Epub 2018 Feb 16.

引用本文的文献

1
Expression Drives Sensitivity to the Antibody-Drug Conjugate Tisotumab Vedotin in Glioblastoma.
Cancers (Basel). 2025 Feb 27;17(5):834. doi: 10.3390/cancers17050834.
3
IDH inhibition in gliomas: from preclinical models to clinical trials.
Nat Rev Neurol. 2024 Jul;20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17.
4
Oncogenes and cancer associated thrombosis: what can we learn from single cell genomics about risks and mechanisms?
Front Med (Lausanne). 2023 Dec 20;10:1252417. doi: 10.3389/fmed.2023.1252417. eCollection 2023.
5
The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis.
Curr Mol Med. 2024;24(9):1135-1151. doi: 10.2174/0115665240258746230919165935.
6
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling.
Cancer Cell. 2023 Aug 14;41(8):1480-1497.e9. doi: 10.1016/j.ccell.2023.06.007. Epub 2023 Jul 13.
8
Modeling glioblastoma complexity with organoids for personalized treatments.
Trends Mol Med. 2023 Apr;29(4):282-296. doi: 10.1016/j.molmed.2023.01.002. Epub 2023 Feb 15.
9
Determining venous thromboembolism risk in patients with adult-type diffuse glioma.
Blood. 2023 Mar 16;141(11):1322-1336. doi: 10.1182/blood.2022017858.
10
A Novel Extracellular Matrix Gene-Based Prognostic Model to Predict Overall Survive in Patients With Glioblastoma.
Front Genet. 2022 Jun 17;13:851427. doi: 10.3389/fgene.2022.851427. eCollection 2022.

本文引用的文献

1
IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma.
J Cancer. 2018 Feb 28;9(6):998-1005. doi: 10.7150/jca.22915. eCollection 2018.
2
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Nat Med. 2018 Feb;24(2):176-185. doi: 10.1038/nm.4475. Epub 2018 Jan 15.
4
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant .
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15.
6
GlioVis data portal for visualization and analysis of brain tumor expression datasets.
Neuro Oncol. 2017 Jan;19(1):139-141. doi: 10.1093/neuonc/now247. Epub 2016 Nov 9.
7
Mutant IDH1 and thrombosis in gliomas.
Acta Neuropathol. 2016 Dec;132(6):917-930. doi: 10.1007/s00401-016-1620-7. Epub 2016 Sep 23.
9
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.
10
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Semin Cancer Biol. 2015 Dec;35 Suppl:S244-S275. doi: 10.1016/j.semcancer.2015.03.008. Epub 2015 Apr 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验